Zepbound and Mounjaro contain the same active drug — tirzepatide — in the same pens at the same doses, but they have different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management in obesity and, more recently, obstructive sleep apnea in obese adults. Zepbound is not FDA-approved as a diabetes treatment, although physicians sometimes prescribe it off-label for metabolic reasons, especially when access or insurance favors one label over the other.
Same Drug, Different Labels
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| Dose strengths | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg weekly | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg weekly |
| FDA approval | May 2022 (T2D) | November 2023 (obesity); December 2024 (OSA) |
| Primary indication | Type 2 diabetes glucose control | Chronic weight management; obstructive sleep apnea |
| Typical payer coverage | Diabetes formularies; often covered | Anti-obesity formulary; coverage variable |
| Outcome trials | SURPASS program | SURMOUNT program |
| Pen device | KwikPen auto-injector | KwikPen auto-injector (same) |
Chemically and pharmacologically, the drug in a Mounjaro pen is identical to the drug in a Zepbound pen. The labels differ because they describe different approved uses based on different clinical trial populations.
Why the Two Separate Labels Exist
FDA approval is indication-specific. Eli Lilly first ran clinical trials (the SURPASS program) in patients with type 2 diabetes; that data supported the Mounjaro label in 2022. Separately, the SURMOUNT program tested tirzepatide in obese patients without diabetes for weight-loss outcomes, leading to the Zepbound approval in late 2023. Later SURMOUNT trials expanded into cardiovascular, kidney, and sleep-apnea outcomes in the obese population.
The two labels allow:
- Distinct promotional and prescribing workflows
- Separate savings and patient-assistance programs
- Different insurance formulary placement (diabetes vs anti-obesity)
- Clearer outcome-trial referencing for clinicians
Does Zepbound Lower Blood Sugar?
Yes — because it is the same molecule, it has the same dual GLP-1/GIP receptor activity that lowers glucose. In obesity trials the patients without diabetes saw modest glucose drops; in those with prediabetes at baseline, fasting glucose and A1C often moved into the normal range. Zepbound is not a diabetes drug by label, but it behaves like one biochemically.
When Clinicians Use Zepbound for Patients With Diabetes
- Access or supply. Pharmacy availability can favor one label over the other.
- Insurance coverage. Some plans cover Zepbound (via obesity formulary) more generously than Mounjaro, or vice versa.
- Cash-pay options. LillyDirect and other direct-to-patient programs may offer one label at a better price.
- Prediabetes plus obesity. Patients who do not formally meet diabetes criteria but have significant weight and metabolic issues may fit Zepbound’s label more cleanly.
- Cardiovascular risk in obesity. The SELECT-style evidence and SURMOUNT-MMO program support cardiovascular benefit in obese patients.
Using Zepbound specifically to treat type 2 diabetes is off-label. Clinicians are permitted to prescribe off-label, but insurance coverage, documentation, and patient counseling differ.
Clinical Results
| Metric | SURPASS-2 (Mounjaro, T2D) | SURMOUNT-1 (Zepbound, Obesity) |
|---|---|---|
| Weight change at 40 to 72 weeks | −7 to −12% (dose-dependent) | −15 to −22% (dose-dependent) |
| A1C reduction | −2.0 to −2.5% at 40 weeks | Not the primary endpoint; modest drops |
| Nausea rate | 18 to 25% | 25 to 30% |
| Discontinuation for GI side effects | ~4 to 7% | ~4 to 7% |
The higher weight-loss magnitude in SURMOUNT reflects higher starting BMI and longer trial duration, not a different drug.
Who Should Use Mounjaro vs Zepbound
- Type 2 diabetes, any BMI: Mounjaro is the on-label choice.
- Obesity, no diabetes: Zepbound is on-label.
- Prediabetes plus obesity: Zepbound often fits the label more cleanly than Mounjaro; discuss with your clinician.
- Obstructive sleep apnea with obesity: Zepbound has a specific label approval for this indication.
- Type 2 diabetes and obesity: Mounjaro is typically the first choice, but insurance and supply dynamics sometimes push toward Zepbound.
Insurance Coverage Differences
- Most commercial plans place Mounjaro on the diabetes formulary with moderate copays when coverage exists.
- Anti-obesity drugs including Zepbound are less consistently covered; some plans explicitly exclude them.
- Medicare Part D has historically excluded anti-obesity drugs by statute, but Zepbound’s OSA and cardiovascular labels may change that in specific cases.
- LillyDirect offers Zepbound at a flat self-pay price for eligible patients without insurance coverage.
Side Effects, Storage, and Injection Technique
Because the drug and pen are identical, side effects, storage rules, and injection technique are the same as Mounjaro. See our related guides on Mounjaro diarrhea and Zepbound nausea for management of GI side effects that are common across both labels.
Related Reading
For broader context on GLP-1 therapy, see our treatment hub and our guide to reversing prediabetes, which covers the lifestyle foundation these drugs support rather than replace.
The Bottom Line
Zepbound is tirzepatide — the same drug as Mounjaro — but it is not FDA-approved for diabetes. For type 2 diabetes, Mounjaro is the on-label choice. For obesity with or without prediabetes, Zepbound is appropriate. If your clinician recommends one over the other, it is usually based on your diagnosis, insurance formulary, supply status, and cost — not on a difference in the drug itself. Confirm the indication, understand the coverage implications, and follow the same dose-titration schedule either way.
